Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON51761
NL-OMON51761
Completed
Not Applicable

A Randomized, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of REC-4881 in Healthy Volunteers - SAD and FE study to assess the safety, tolerability, PK and PD of REC-4881

Recursion Pharmaceuticals, Inc.0 sites24 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsColon cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Colon cancer
Sponsor
Recursion Pharmaceuticals, Inc.
Enrollment
24
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\. Male or female participant aged 18 to 50 years, inclusive.
  • •2\. Participant must provide written informed consent.
  • •3\. Participant's body mass index is between 18 and 32 kg/m2, inclusive, with a
  • •minimum body weight of 50 kg.
  • •4\. Participant is healthy, as determined by pre\-study medical history,physical
  • •examination (including neurologic examination), vital signs, and 12\-lead ECG.

Exclusion Criteria

  • •1\. Participant has any clinically significant laboratory abnormality or illness
  • •which, in the opinion of the Investigator, could interfere with the conduct or
  • •interpretation of the study or put the participant at risk.
  • •2\. Participant has a history of gall bladder disorder or complication,
  • •including cholelithiasis.
  • •3\. Participant has a history of abnormal left ventricular ejection fraction.
  • •4\. Participant has a history of corneal erosions, corneal degenerations, active
  • •or recurrent keratitis, and other forms of serious ocular surface inflammatory
  • •conditions.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 1
A Randomized, Placebo-Controlled, Sequential Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female VolunteersInflammatory Bowel DiseaseUlcerative colitisCrohn's DiseaseInflammatory and Immune System - Autoimmune diseasesOral and Gastrointestinal - Crohn's disease
ACTRN12618001210268andos Biopharma Australia Pty Ltd70
Completed
Not Applicable
A phase 1, placebo-controlled, single ascending-dose study to assess the safety, tolerability and pharmacokinetics of OTL-038 injection in healthy volunteerscancercarcinoma10027655
NL-OMON40422On Target Laboratories LLC30
Recruiting
Phase 1
A Clinical trial of a drug (ADV-1002401) to evaluate safety, tolerability, in adult male Type-II diabetic subjectsHealth Condition 1: E116- Type 2 diabetes mellitus with other specified complications
CTRI/2011/04/001661Advinus Therapeutics Ltd60
Completed
Not Applicable
A Randomized, Blinded, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB033 in Healthy Adult VolunteersdemyelinationMS10012303
NL-OMON32724Biogen64
Completed
Not Applicable
A Placebo-Controlled, Randomized, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Patients with Molecularly Defined Genetic Muscular DystrophiesFacioscapulohumeral muscular dystrophygenetic myopathy10028396
NL-OMON42284aTyr Pharma, Inc.16